Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

HIV drug weight gain mystery: healthy volunteers sought for clues

NCT ID NCT05652478

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 58 times

Summary

This study tests four different HIV drug regimens in 120 healthy volunteers to see how they affect metabolism and weight. Participants take one of the drugs or a combination for four weeks, with blood tests, body scans, and optional fat biopsies. The goal is to understand why some HIV drugs cause weight gain, which could lead to better treatments for people with HIV.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dolutegravir and Tenofovir alafenamide (HIV drugs)
What this could lead to
If successful, this study could help explain why some HIV drugs cause weight gain, leading to safer treatments for people with HIV.
What could go wrong
This is an early phase 2 study in healthy volunteers, not people with HIV, so results may not directly apply. The study is small and short-term, so long-term effects remain unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Aged 18 to 55 years. * Able to provide informed consent. * Willing to allow samples and data to be stored and shared for future research. * Agrees to use a barrier method of contraception or abstain from sexual activity starting at screening though the end of study participation. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Current infection with HIV or hepatitis A, B, or C. * Body mass index (BMI) \<18.5 kg/m\^2 or \>30.0 kg/m\^2. * Weight change \>5% in the past 6 months. * History of or current cardiovascular disease such as congestive heart failure, heart block, or clinically relevant abnormal ECG as determined by investigators. * History of or current liver disease or alanine transaminase serum level \>2x upper limit of normal. * History of or current kidney disease or renal insufficiency, or estimated creatinine clearance \<=80 mL/min (Modification of Diet in Renal Disease equation). * Current cancer or history of cancer within 5 years of screening, with the exception of squamous cell carcinoma or basal cell carcinoma that is localized and does not require systemic therapy. * History of bariatric surgery. * Diabetes mellitus as defined by a prior diagnosis or a hemoglobin A1c of \>6.4 percent on screening labs. * Fasting serum glucose \>126 mg/dL. * History of or current hypo- or hyper-thyroid or abnormal TSH, except minor deviations deemed to be of no clinical significance by the investigator. * History of chronic obstructive pulmonary disease. * Psychological conditions by self-report, such as (but not limited to) clinical depression, or bipolar disorders, which would be incompatible with safe and successful participation in this study. * Pregnancy or within 1 year post-partum. * Breastfeeding. * Blood pressure \>140/90 mm Hg or current antihypertensive therapy. * Hemoglobin that is either 10 percent below the lower limit or 10 percent above the upper limit of the normal range for the Clinical Center Laboratory (acceptable ranges: females 10.08-17.27 g/dL, males 12.33-19.25 g/dL). * History of illicit drug, opioid, or alcohol abuse within the last 5 years; current use of illicit drugs or opioids (by history) or excessive alcohol (CAGE assessment score \>=2). * Current use of the following prescription or over-the-counter medications and supplements: * Carbamazepine * Oxcarbazepine * Phenobarbital * Phenytoin * Primidone * Rifabutin * Rifampin * Rifapentine * St. John's wort (Hypericum perforatum) * Cation-containing antacids or laxatives * Sucralfate * Buffered medications * Oral calcium, iron, magnesium, or zinc supplements, including multivitamins containing these polyvalent cations * Dalfampridine * Metformin * Dofetilide * Thyroid medications * Corticosteroids * Weight loss medications, including prescription drugs (eg, semaglutide and tirzepatide) and over-the-counter diet pills * Use of TAF, TDF, and/or FTC for the purpose of HIV PrEP or in a research study within the past 6 months. * Any history of exposure to cabotegravir or lenacapavir (eg, as HIV PrEP or as a participant in a research study for these drugs). * Current use of prescription or nonprescriptive medications that may have interactions with study drugs or confound the study measurements as determined by the investigators. * History of adverse or allergic reactions to the study drugs. * Daily caffeine intake \>500 mg (about 4 cups of coffee). * Current smoker or user of tobacco products. * A change in the participant's diet and/or exercise regimen in the past 3 months or during the timeframe of the study period that, in the opinion of the investigator, would compromise the integrity of the data. * High-risk sexual activity as determined by the investigators, and/or inability or unwillingness to use barrier contraception during the protocol. * Any other condition, medication, or dietary pattern that, in the opinion of the investigators, increases risk to the participant, prevents the participant from complying with study procedures, prevents the participant from completing the study, or interferes with the interpretation of study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.